1. All nine nominees were elected to the Hamilton Thorne Board of Directors, and each director elected will continue to hold office until the Company’s next annual meeting of shareholders, or until the director resigns or a successor is elected or appointed. The voting results for directors were as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
98,164,035 | 99.97% | 27,800 | 0.03% | |
98,163,535 | 99.97% | 28,300 | 0.03% | |
94,556,717 | 96.30% | 3,635,118 | 3.70% | |
94,432,052 | 96.17% | 3,759,783 | 3.83% | |
98,163,535 | 99.97% | 28,300 | 0.03% | |
98,163,535 | 99.97% | 28,300 | 0.03% | |
94,591,532 | 96.33% | 3,600,303 | 3.67% | |
Ekatarina Torchilin | 97,735,452 | 99.54% | 456,383 | 0.46% |
97,735,752 | 99.54% | 456,083 | 0.46% | |
2. Shareholders re-appointed
3. Shareholders approved the proposed share consolidation resolution as described in the Circular, with 99.92% of all votes cast in favor.
4. Shareholders approved the proposed Long Term Equity Incentive Plan amendment resolution as described in the Circular, with 94.33% of all votes cast in favor.
About
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech,
For more information, please contact:
978-921-2050 ir@hamiltonthorne.ltd | 978-921-2050 ir@hamiltonthorne.ltd | |
Bristol Investor Relations 905-326-1888 glen@bristolir.com | ||
![](https://ml.globenewswire.com/media/MTFkNDI5MTYtZTJkZi00OTlkLWExMTEtM2IzMjQwYTJkMjdlLTEwOTU4OTI=/tiny/Hamilton-Thorne-Ltd-.png)
2024 GlobeNewswire, Inc., source